Breakthrough in Battery Longevity Through Advanced Membrane Technology Researchers have developed a groundbreaking approach to significantly extend the lifespan of…
Scientists have developed a series of novel chalcone-sulfonate hybrid compounds that reportedly target multiple enzymes involved in Alzheimer’s disease pathogenesis. According to research findings, one compound in particular shows significant potential as a multi-target therapeutic agent against this neurodegenerative condition.
Researchers have synthesized and evaluated a series of novel chalcone derivatives that reportedly target multiple pathological mechanisms involved in Alzheimer’s disease, according to recent scientific reports. The study, published in Scientific Reports, details the development of compounds combining chalcone, sulfonyl, and allyl frameworks designed to simultaneously inhibit several key enzymes implicated in Alzheimer’s progression.
